全文获取类型
收费全文 | 7493篇 |
免费 | 319篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 34篇 |
儿科学 | 119篇 |
妇产科学 | 89篇 |
基础医学 | 769篇 |
口腔科学 | 155篇 |
临床医学 | 498篇 |
内科学 | 1949篇 |
皮肤病学 | 84篇 |
神经病学 | 600篇 |
特种医学 | 295篇 |
外科学 | 1299篇 |
综合类 | 35篇 |
预防医学 | 158篇 |
眼科学 | 446篇 |
药学 | 460篇 |
中国医学 | 16篇 |
肿瘤学 | 845篇 |
出版年
2021年 | 98篇 |
2020年 | 65篇 |
2019年 | 102篇 |
2018年 | 114篇 |
2017年 | 107篇 |
2016年 | 156篇 |
2015年 | 130篇 |
2014年 | 179篇 |
2013年 | 195篇 |
2012年 | 330篇 |
2011年 | 320篇 |
2010年 | 200篇 |
2009年 | 170篇 |
2008年 | 303篇 |
2007年 | 311篇 |
2006年 | 344篇 |
2005年 | 318篇 |
2004年 | 325篇 |
2003年 | 310篇 |
2002年 | 345篇 |
2001年 | 304篇 |
2000年 | 326篇 |
1999年 | 271篇 |
1998年 | 88篇 |
1997年 | 84篇 |
1996年 | 65篇 |
1995年 | 62篇 |
1994年 | 62篇 |
1993年 | 54篇 |
1992年 | 199篇 |
1991年 | 170篇 |
1990年 | 153篇 |
1989年 | 167篇 |
1988年 | 153篇 |
1987年 | 97篇 |
1986年 | 136篇 |
1985年 | 127篇 |
1984年 | 78篇 |
1983年 | 77篇 |
1979年 | 73篇 |
1978年 | 46篇 |
1977年 | 46篇 |
1975年 | 33篇 |
1974年 | 47篇 |
1973年 | 49篇 |
1972年 | 45篇 |
1971年 | 58篇 |
1970年 | 39篇 |
1969年 | 41篇 |
1968年 | 44篇 |
排序方式: 共有7851条查询结果,搜索用时 15 毫秒
1.
2.
Mayuko Kinoshita Haruka Kaneko Lizu Liu Masashi Nagao Ryo Sadatsuki 《Modern rheumatology / the Japan Rheumatism Association》2019,29(1):157-164
Objectives: To examine the factors associated with increase in lumbar spine bone mineral density (LS-BMD) by bisphosphonates (BPs) with active vitamin D analog (aVD).Methods: Two independent postmenopausal osteoporotic patients treated by BPs with aVD for 24 months (Study 1: n?=?93, Study 2: n?=?99) were retrospectively analyzed.Results: In Study 1, LS-BMD of the patients significantly increased for 24 m (5.4%, p?.001). A multiple regression analysis among baseline characteristics revealed that serum calcium (sCa: 8.5–10.5?mg/dL) was associated with an increased LS-BMD by treatment (r2: 0.088, p?=?.02). While average sCa of the patients was 9.2?mg/dL before treatment, it increased time-dependently to 9.6?mg/dL for 24 m by treatment. As each patient had their LS-BMD five times during the study, there were four instances of %LS-BMD in each patient, resulting in 372 instances of %LS-BMD in Study 1. The smallest Akaike’s information criterion value for the most appropriate cut-off levels of sCa for %LS-BMD by treatment every 6 m was 9.3?mg/dL. The %LS-BMD by treatment for 6 m during 24 m period in patients with sCa ≥9.3?mg/dL (1.5%) was significantly higher than that in patients with sCa <9.3?mg/dL (0.8%, p?=?.038). The results of Study 2 were similar to those of Study 1, confirming the phenomena observed.Conclusion: sCa was associated with an increased LS-BMD by BPs with aVD. 相似文献
3.
4.
5.
6.
Sho Tamai Masashi Kinoshita Hemragul Sabit Takuya Furuta Katsuyoshi Miyashita Kaori Yoshimura Taku Homma Kenichi Harada Mitsutoshi Nakada 《Neuropathology》2019,39(3):218-223
Glioblastoma (GBM) with primitive neuronal component (GBM‐PNC) is a rare GBM subtype recently categorized by the World Health Organization in the revised classification system of 2016. Extracranial metastases originating from GBM‐PNC are rare and metastasis to solid organs has never been reported. Herein, we present the first case of metastasis of GBM‐PNC to the lung. A 49‐year‐old man presenting with headache was diagnosed with multiple tumors adhering to the dura matter in the right temporal lobe. Despite surgery and chemoradiotherapy, 2 months after the initial therapy, the patient presented with CSF dissemination and lung metastases. The patient succumbed to the disease 12 months after the first surgery. We discuss the possibility that GBM‐PNC may constitute a subtype of glioma with particularly poor prognosis, tending to dissemination and metastasis. Our results suggest that a complementary regular inspection of the whole body via CT may be recommended for the follow‐up of patients with GBM‐ PNC. 相似文献
7.
Takeshi Nagashima Ken Yamaguchi Kenichi Urakami Yuji Shimoda Sumiko Ohnami Keiichi Ohshima Tomoe Tanabe Akane Naruoka Fukumi Kamada Masakuni Serizawa Keiichi Hatakeyama Kenya Matsumura Shumpei Ohnami Koji Maruyama Tohru Mochizuki Masatoshi Kusuhara Akio Shiomi Yasuhisa Ohde Masanori Terashima Katsuhiko Uesaka Tetsuro Onitsuka Seiichiro Nishimura Yasuyuki Hirashima Nakamasa Hayashi Yoshio Kiyohara Yasuhiro Tsubosa Hirohisa Katagiri Masashi Niwakawa Kaoru Takahashi Hiroya Kashiwagi Masahiro Nakagawa Yuji Ishida Takashi Sugino Mitsuru Takahashi Yasuto Akiyama 《Cancer science》2020,111(2):687-699
This study aimed to establish the Japanese Cancer Genome Atlas (JCGA) using data from fresh frozen tumor tissues obtained from 5143 Japanese cancer patients, including those with colorectal cancer (31.6%), lung cancer (16.5%), gastric cancer (10.8%) and other cancers (41.1%). The results are part of a single‐center study called “High‐tech Omics‐based Patient Evaluation” or “Project HOPE” conducted at the Shizuoka Cancer Center, Japan. All DNA samples and most RNA samples were analyzed using whole‐exome sequencing, cancer gene panel sequencing, fusion gene panel sequencing and microarray gene expression profiling, and the results were annotated using an analysis pipeline termed “Shizuoka Multi‐omics Analysis Protocol” developed in‐house. Somatic driver alterations were identified in 72.2% of samples in 362 genes (average, 2.3 driver events per sample). Actionable information on drugs that is applicable in the current clinical setting was associated with 11.3% of samples. When including those drugs that are used for investigative purposes, actionable information was assigned to 55.0% of samples. Germline analysis revealed pathogenic mutations in hereditary cancer genes in 9.2% of samples, among which 12.2% were confirmed as pathogenic mutations by confirmatory test. Pathogenic mutations associated with non–cancerous hereditary diseases were detected in 0.4% of samples. Tumor mutation burden (TMB) analysis revealed 5.4% of samples as having the hypermutator phenotype (TMB ≥ 20). Clonal hematopoiesis was observed in 8.4% of samples. Thus, the JCGA dataset and the analytical procedures constitute a fundamental resource for genomic medicine for Japanese cancer patients. 相似文献
8.
Katsunobu Oyama Sachio Fushida Tomoya Tsukada Jun Kinoshita Toshifumi Watanabe Masatoshi Shoji Shinichi Nakanuma Koichi Okamoto Seisho Sakai Isamu Makino Keishi Nakamura Hironori Hayashi Masafumi Inokuchi Hisatoshi Nakagawara Tomoharu Miyashita Hidehiro Tajima Hiroyuki Takamura Itasu Ninomiya Hirohisa Kitagawa Takashi Fujimura Ryousuke Tajiri Akishi Ooi Tetsuo Ohta 《Journal of gastroenterology》2015,50(1):121-122
9.
10.
Yosuke Mitsui Nahoko Tomonobu Masami Watanabe Rie Kinoshita I Wayan Sumardika Chen Youyi Hitoshi Murata Ken-ichi Yamamoto Takuya Sadahira Acosta Gonzalez Herik Rodrigo Hitoshi Takamatsu Kota Araki Akira Yamauchi Masahiro Yamamura Hideyo Fujiwara Yusuke Inoue Junichiro Futami Ken Saito Hidekazu Iioka Eisaku Kondo Masahiro Nishibori Shinichi Toyooka Yasuhiko Yamamoto Yasutomo Nasu Masakiyo Sakaguchi 《Oncology research》2019,27(8):945-956
S100A11, a member of the S100 family of proteins, is actively secreted from pancreatic ductal adenocarcinoma (PDAC) cells. However, the role of the extracellular S100A11 in PDAC progression remains unclear.
In the present study, we investigated the extracellular role of S100A11 in crosstalking between PDAC cells
and surrounding fibroblasts in PDAC progression. An abundant S100A11 secreted from pancreatic cancer cells stimulated neighboring fibroblasts through receptor for advanced glycation end products (RAGE)
upon S100A11 binding and was followed by not only an enhanced cancer cell motility in vitro but also an
increased number of the PDAC-derived circulating tumor cells (CTCs) in vivo. Mechanistic investigation of
RAGE downstream in fibroblasts revealed a novel contribution of a mitogen-activated protein kinase kinase
kinase (MAPKKK), tumor progression locus 2 (TPL2), which is required for positive regulation of PDAC
cell motility through induction of cyclooxygenase 2 (COX2) and its catalyzed production of prostaglandin
E2 (PGE2), a strong chemoattractive fatty acid. The extracellularly released PGE2 from fibroblasts was
required for the rise in cellular migration as well as infiltration of their adjacent PDAC cells in a coculture setting. Taken together, our data reveal a novel role of the secretory S100A11 in PDAC disseminative
progression through activation of surrounding fibroblasts triggered by the S100A11–RAGE–TPL2–COX2
pathway. The findings of this study will contribute to the establishment of a novel therapeutic antidote to
PDACs that are difficult to treat by regulating cancer-associated fibroblasts (CAFs) through targeting the
identified pathway. 相似文献